Skip to main content
. Author manuscript; available in PMC: 2013 Dec 1.
Published in final edited form as: Int J Cancer. 2012 Apr 24;131(11):2562–2572. doi: 10.1002/ijc.27534

Figure 3.

Figure 3

Growth inhibitory activity of immune sera. A. SUM159 cells were treated with 2% hDR5 immune serum in an MTT-based assay as described in Material and Methods. Agonist mAb 631 at 5 μg/ml was the positive control. B. Activity of immune sera induced by hDR5 vaccines encoding wild type or death domain defective constructs measured by MTT assay. Controls were blank pVax1 (Vector) and hDR5 agonist mAb631. Significance was determined using a 2-tailed Student’s t-test. No significant difference was observed between individual hDR5 vaccines.